Ideal Protein Launches Whitepaper Unveiling Synergistic Approach to Enhance GLP-1 Medication Outcomes

New resource highlights critical role of lifestyle interventions in maximizing weight loss success and addressing limitations of GLP-1 therapies


MONTREAL, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ideal Protein, a leader in scientifically validated weight management solutions, today announced the release of its groundbreaking whitepaper“Maximizing the Promise of GLP-1 Medications” This comprehensive document explores how integrating GLP-1 receptor agonists—such as Ozempic®, Wegovy®, and Zepbound™—with structured nutrition, coaching, and behavioral support can bridge the growing care gap in obesity treatment and drive sustainable health outcomes.

GLP-1 medications have revolutionized obesity treatment, yet challenges like affordability, side effects, muscle loss, and weight regain persist. According to the whitepaper, 30% of patients discontinue GLP-1s within 30 days, while studies show 40-60% of total weight lost on these medications may come from muscle mass, exacerbating long-term health risks. Ideal Protein’s protocol addresses these issues through a protein-forward dietary approach, personalized coaching, and micronutrient support, proven to preserve 95-98% of lean body mass during weight loss.

“As we move into the era of improved weight loss medication’s such as GLP-1s, it is important to remember that the treatment of obesity and nutritional metabolic disorders requires a multiprong approach.” said Dr Douglas Rothrock, MD, FABIM, FACC, FABOM, Chief Scientific Advisor at Ideal Protein. “Nutritional training, behavior, modification, and physical activity are still key to maintaining a proper weight and metabolic reset. Ideal Protein is in the perfect position to be the partner with weight loss medication’s and GLP-1s to promote a broad and significant metabolic reset with weight loss.”

Key Whitepaper Insights:

  • Muscle Preservation: On average, GLP-1 users lose 10% of muscle mass within 1–4 years. Ideal Protein’s high-protein protocol helped participants preserve 95-98% of lean mass during weight loss, countering sarcopenia risks.
  • Reduced Side Effects: Fiber-rich, low-carb nutrition alleviates gastrointestinal issues linked to GLP-1 use, improving adherence.
  • Combatting Weight Regain: Coaching and structured nutrition help patients maintain ≥5% weight loss at 8 years, even after stopping medication.
  • Nutritional Safety Net: Micronutrient supplementation addresses deficiencies caused by reduced food intake on GLP-1s.
  • Cost-Effective Care: Partnerships with lifestyle programs like Ideal Protein likely to enhance medication efficacy, reducing long-term healthcare burdens.

The protocol’s three-phase structure (Weight Loss, Stabilization, Maintenance) ensures seamless alignment with GLP-1 therapy. For example, during the Maintenance Phase, ongoing coaching helps patients sustain habits post-medication, while gradual carbohydrate reintroduction in the Stabilization Phase stabilizes metabolism. “Our protocol was built for metabolic resilience,” said Dr. Tran Tien Chanh, Founder of the Ideal Protein Protocol. “Pairing it with GLP-1s isn’t just logical—it’s essential to overcoming the limitations of the medication alone.”

With over 70 new GLP-1 therapies in development, the document underscores the urgency of integrating holistic care models into treatment plans. “Our goal is to empower clinicians and patients to harness the full potential of GLP-1s,” Dr. Tran added. “This whitepaper provides actionable strategies to turn short-term weight loss into lifelong health.”

Download the full whitepaper: Maximizing the Promise of GLP-1 Medications

About Ideal Protein

Ideal Protein has pioneered protein-forward weight management solutions since 2004. Its protocol, developed by Dr. Tran Tien Chanh, combines medical expertise with personalized coaching to promote sustainable metabolic health. The company partners with healthcare providers worldwide to address obesity through science-backed nutrition and behavior modification.

Media Contact:
Carolyn Lemm Espinoza, Development Engagement Manager, Ideal Protein
+1 217-778-4382 | clespinoza@idealprotein.com


Ozempic® and Wegovy® are registered trademarks of Novo Nordisk. Zepbound™ is a trademark of Eli Lilly and Company.

Follow Us: Linkedin | X (Twitter) | Facebook | Instagram
For updates, visit: IdealProtein.com


This press release is for informational purposes only and does not constitute medical advice. Consult a healthcare professional before starting any weight loss program.